Genentech Obligations Sample Clauses

Genentech Obligations. Except with respect to obligations of Immunex --------------------- under Section 3.4(b) above, Genentech shall use Commercially Reasonable -------------- Best Efforts to timely prepare and obtain, and Commercially Reasonable Efforts to maintain, all regulatory approvals that are required to manufacture Bulk Drug at the Genentech Facility in South San Francisco, California, including, without limitation, the preparation, filing and maintenance of supplements to Genentech's existing FDA licenses (and drug master file), and Genentech shall reasonably assist Immunex in meeting its obligations under this Section 3.4, including, without ----------- limitation, reasonably assisting with the preparation and review of the drafts of the chemistry, manufacturing and controls sections of the sBLA to be filed by Immunex with FDA. Genentech shall also reasonably assist Immunex in responding to requests and inquiries from the FDA prior to, during and after regulatory review periods and by attending meetings with such regulatory authorities to the extent it is essential for Genentech to participate given its unique * Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. The omitted portions of this exhibit have been filed separately with the SEC. knowledge or its status as manufacturer of Bulk Drug under this Agreement. Genentech personnel shall also facilitate pre-approval inspection of the Genentech Facility conducted by such regulatory authorities. The assistance to be provided by Genentech under this Section 3.4(c) shall be provided at no additional cost to Immunex, -------------- except as otherwise provided in Sections 3.9 and 4.5 hereof. --------------------
Sample 1
AutoNDA by SimpleDocs
Genentech Obligations. In the event that XOMA cannot find a Third Party to manufacture that is acceptable to Genentech, and to the extent the manufacture of Licensed Product for XOMA will not unreasonably, and adversely impact Genentech or its obligations to Third Parties or Affiliates, then Genentech will continue to supply Licensed Product in bulk form only until the earlier of (i) [*] from XOMA's receipt of notice of Genentech's election not to produce or supply or (ii) [*] from the date on which Genentech and XOMA find a mutually acceptable manufacturer. In the event Genentech does approve of a Third Party to manufacture Licensed Product, and to the extent the manufacture of bulk Licensed Product for XOMA will not materially and unreasonably adversely impact Genentech or its obligations to Third Parties or Affiliates, Genentech shall, at XOMA's request, continue to manufacture Licensed Product in bulk form for up to [*] after Genentech and XOMA approve a Third Party manufacturer. Notwithstanding anything to the contrary, at a minimum, Genentech must supply XOMA with the amount of Licensed Product in bulk form which is yielded from one successful [*] Run each year that Genentech is obligated to supply Licensed Product hereunder.
Sample 1
Genentech Obligations 
Sample 1

Related to Genentech Obligations

  • Royalty Obligations Part 2.7(e) of the Disclosure Schedule contains a complete and accurate list and summary of all royalties, fees, commissions, and other amounts payable by the Seller to any Person (other than sales commissions paid to employees according to the Seller’s standard commissions plan) upon or for the sale, or distribution of any Seller Product or the use of any Seller IP.

  • Third Party Obligations 3.1. The THIRD PARTY shall:-

  • Development Obligations 1. The College supports the development, production, and dissemination of copyrightable, trademarkable, patentable, and other intellectual properties by its employees.

  • Licensee Obligations 3.1 The Licensee is responsible for the installation, operation and maintenance of telecommunication lines, equipment, software and other arrangements necessary for the Licensee to receive the Licensed Data from the LME.

  • Valid Obligations The execution, delivery and performance of the Loan Documents have been duly authorized by all necessary corporate action and each represents a legal, valid and binding obligation of Borrower and is fully enforceable according to its terms, except as limited by laws relating to the enforcement of creditors' rights.

  • Supply Obligations Upon Licensor’s request, AbbVie shall either (a) to the extent allowable under such agreements, assign to Licensee or its Affiliates the portion of AbbVie’s agreement(s) with its Third Party manufacturing provider related to the Terminated Antibodies, Terminated Products and placebo used in connection therewith, or alternatively, use Commercially Reasonable Efforts to facilitate Licensor’s entering into a direct supply agreement with such Third Party manufacturing provider of the Terminated Antibodies, Terminated Products and placebo used in connection therewith on comparable terms to those between AbbVie and such Third Party manufacturing provider (in each case assuming AbbVie is then obtaining supply of Terminated Antibodies, Terminated Products or placebo used in connection therewith from a Third Party manufacturing provider) and (b) to the extent AbbVie or its Affiliate is producing its own supply of the Terminated Product, Terminated Antibody or placebo, use Commercially Reasonable Efforts to supply to Licensor the Terminated Antibodies and/or Terminated Products and placebo as requested by Licensor, to the extent reasonably necessary for Licensor’s continued Development and Commercialization of such Terminated Antibodies and/or Terminated Products, until the date on which Licensor notifies AbbVie in writing that Licensor has secured an alternative manufacturer for the Terminated Antibodies and/or Terminated Products, but in no event more for than [***] after the effective date of any expiration or termination of this Agreement. In the case of (b), Licensor shall pay to AbbVie a transfer price for the materials supplied equal to the Manufacturing Cost thereof. Without limiting the foregoing, in either case Licensor shall additionally have the right to immediately have AbbVie commence the transfer of the Manufacturing Process to Licensor or its designee, with such transfer to be carried out in accordance with the terms of Section 3.5.3, applied mutatis mutandis. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.

  • Diligence Obligations NN shall use commercially --------------------- reasonable efforts to achieve each of the following diligence obligations, for at least one Zid Embodiment in the ZSS, no later than the applicable deadline. The standard diligence time periods that ZGI and NN intend to be included in a Pre-Negotiated License under SECTION 7.8 in the situation where a Xxx Xxxx, Zid Protein or a Soluble Embodiment is the Product are recited below. However, both ZGI and NN recognize that specific circumstances surrounding a particular Zid Embodiment may lead the parties to negotiate one or more different diligence time period(s) within a particular Pre-Negotiated License. Under the standard diligence time periods, NN must:

  • Client Obligations 3.1 The Client shall:

  • Joint Obligations A. The University and the student share the responsibility for ensuring the quality of life within the residence halls, their maintenance, furnishings and facilities, and for a physical environment secure from fire and other hazards. The University will work with students to promote effective security of persons and property in the residence halls.

  • Parties’ Obligations The Parties’ obligations under this Agreement will continue notwithstanding the existence of a Material Change.

Time is Money Join Law Insider Premium to draft better contracts faster.